肿瘤过继免疫治疗的研究进展及展望  

The research progress and prospect of adoptive cell therapy of tumors

作　　者：王子源 张锦鹏[1,2] 傅昭粤 孟强[1,2] 宣国云 封仁乾 姜东伯[1] 杨琨[1] WANG Ziyuan1,2, ZHANG Jinpeng1,2, FU Zhaoyue1,2, MENG Qiang1,2, XUAN Guoyun1,2 FENG Renqian1,2, JIANG Dongbo1, YANG Kun1.(1Department of Immunology, School of Basic Medicine, the Fourth Military Medical University; 2Brigade of Cadet, School of Basic Medicine, The Fourth Military Medical University, Xi＇an 710032, Chin)

机构地区：[1]第四军医大学基础医学院免疫学教研室 [2]第四军医大学基础医学院学员旅,西安710032

出　　处：《生命的化学》2018年第1期97-103,共7页Chemistry of Life

基　　金：国家自然科学基金面上项目(81171977)

摘　　要：肿瘤免疫治疗因在肿瘤治疗中具有高效性已成为疗效显著的新型疗法,其中细胞介导的过继免疫治疗是当前研究的热点。与化疗、放疗、手术切除这些传统肿瘤治疗手段相比,由于能够直接杀伤或者激活免疫系统杀伤肿瘤细胞,过继免疫治疗展现出独特的优势和临床应用前景。近些年,研究人员在过继免疫治疗领域取得了大量的研究进展。本文将对肿瘤过继免疫治疗的现状与临床前景进行综述。Due to high efficiency in the treatment of cancer, tumor immunotherapy has become a new effective therapy. Cell-mediated adoptive cell therapy（ACT） is the current research focus. Since ACT can directly kill or stimulate the immune response to kill tumor cells, this therapy has shown its unique advantages and good clinical prospect compared with traditional methods of tumor treatment including chemotherapy, radiotherapy and surgical resection. In recent years, a number of research progresses have made in this field. This paper reviews the situation and clinical prospect of adoptive cell therapy in tumor treatment.

关 键 词：肿瘤免疫治疗 嵌合抗原受体 过继免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]